Nkarta has singled out a group of five patients previously treated with a median of three prior therapies for AML, who were treated with the highest level of NKX101 (three doses at 1.5 billion NK ...

also a researcher in the Neurobiology of Dementias group and Memory Unit at IR Sant Pau, and first author of the article. At present, there is no approved drug that specifically modulates NK cells ...